Satellos Bioscience to Present Phase 1 Data for SAT-3247 at MDA Conference

An update from Satellos Bioscience ( (TSE:MSCL) ) is now available.

Satellos Bioscience announced it will present its first-ever Phase 1 safety and pharmacokinetic data for SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. This presentation marks a significant milestone for Satellos, highlighting the potential of SAT-3247 as a novel treatment for Duchenne muscular dystrophy and its continued progress in clinical trials, which may enhance its position in the biotech industry.

More about Satellos Bioscience

Satellos Bioscience Inc. is a public biotechnology company focused on developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The company is advancing its proprietary oral drug, SAT-3247, aimed at regenerating skeletal muscle in conditions such as Duchenne muscular dystrophy, independent of dystrophin and exon mutation status.

YTD Price Performance: -15.53%

Average Trading Volume: 166,300

Technical Sentiment Consensus Rating: Hold

Current Market Cap: $78.85M

Learn more about MSCL stock on TipRanks’ Stock Analysis page.